

ASCO Annual Meeting, May 31 - June 4, 2019

Presentation Schedule for Winship Cancer Institute of Emory University and Emory University School of Medicine Faculty and Residents



Friday, May 31, 2019

Location	Time	Session Type	Abstract #	Presenter	Title
S504	2:45PM - 5:45PM	Oral Abstract Session		Melinda Gordon Pauly, MD (Session Chair)	Pediatric Oncology 1
S404	4:45PM - 5:00PM	Education Session		Jane Lowe Meisel, MD (Speaker)	Creating Connections and Building Community: Social Media and Physician Quality of Life

Saturday, June 1, 2019

Location	Time	Session Type	Abstract #	Presenter	Title
E451	8:00AM - 9:00AM	Interactive Case-Based Session		Nabil F. Saba, MD (Speaker)	Does Stage I HPV-Positive Oropharynx Cancer Really Need Combined Modality Therapy?
Hall A	8:00AM - 11:00AM	Poster Session (#417)	10035	Jason R. Fangusaro, MD	A phase II clinical study of pomalidomide (CC-4047) monotherapy for children and young adults with recurrent or progressive primary brain tumors.
Hall A	8:00AM - 11:00AM	Poster Session (#446)	10064	Sharon M. Castellino, MD, MSc	Performance of FACT-GOG-Ntx to assess chemotherapy-induced peripheral neuropathy (CIPN) in pediatric hodgkin lymphoma (HL) patients
E350	8:30AM - 8:45AM	Education Session		William C. Wood, MD, FASCO	Continued Professional Engagement and Personal Fulfillment for Clinicians After Full-Time Practice
Hall A	1:15PM - 4:15PM	Poster Session (#38)	6049	Dong Moon Shin, MD, FACP	Phase 1b study of chemoprevention with green tea polyphenon E (PPE) and epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (Erlotinib) in patients (pts) with advanced premalignant (AP) lesion of the head and neck.
Hall A	1:15PM - 4:15PM	Poster Board (#278)	6587	Demetria Joy Smith-Graziani, MD	Prospective study of pain outcomes associated with contralateral prophylactic mastectomy in women with nonhereditary breast cancer.
S102	4:30PM - 6:00PM	Poster Discussion Session		Katherine S. Virgo, PhD, FASCO (Session Chair)	Health Services Research, Clinical Informatics, and Quality of Care

Swissôtel 7:00PM - 9:00PM Winship Reception Élevé Riverview, Penthouse Ballroom, 42nd floor, 323 East Upper Wacker Drive, Chicago, IL 60601

Sunday, June 2, 2019

Location	Time	Session Type	Abstract #	Presenter	Title
Hall A	8:00AM - 11:00AM	Poster Session (#143)	1062	Urvi Patel, MD	The clinical utility of strict laboratory monitoring of CDK 4/6 inhibitors in metastatic breast cancer patients.
Hall A	8:00AM - 11:00AM	Poster Session (#240)	2051	Robert H. Press, MD	The timing of chemoradiotherapy after surgical resection and its impact on overall survival in glioblastoma.
Hall A	8:00AM - 11:00AM	Poster Session (#271)	8515	Taofeek Kunle Owonikoko, MD, PhD, MS	A randomized phase II study of tremelimumab and durvalumab with or without radiation for patients with relapsed small cell lung cancer (SCLC).
Hall A	8:00AM - 11:00AM	Poster Session (#345)	9022	Taofeek Kunle Owonikoko, MD, PhD, MS	A phase II study of talazoparib (BMN 673) in patients with homologous recombination repair deficiency (HRRD) positive stage IV squamous cell lung cancer (Lung-MAP Sub-Study, S1400G).
Hall A	8:00AM - 11:00AM	Poster Session (#365)	9024	Bassel Nazha, MD, MPH	Evaluating the role of race in outcome of advanced non-small cell lung cancer (NSCLC) patients treated with immune checkpoint inhibitor (ICI): Our institutional experience.
E451	9:57AM - 10:09AM	Oral Abstract Session	8001	Sagar Lonial, MD	E3A06: Randomized phase III trial of lenalidomide versus observation alone in patients with asymptomatic high-risk smoldering multiple myeloma
S406	11:15AM - 12:45PM	Poster Discussion Session	8515	Taofeek Kunle Owonikoko, MD, PhD, MS	A randomized phase II study of tremelimumab and durvalumab with or without radiation for patients with relapsed small cell lung cancer (SCLC).
S100bc	11:30AM - 12:10PM	Interactive Case-Based Session		Ragini Reiney Kudchadkar, MD (Chair)	Case Presentations and Management of Common Immunotherapy Toxicities (Colitis, Pneumonitis, Hepatitis)
S406	11:37AM - 11:49AM	Poster Discussion Session	8510, 8511, 8512	Kristin Ann Higgins, MD (Discussant)	Adding to Chemoradiation in Locally Advanced NSCLC
E451	11:45AM - 11:57AM	Oral Abstract Session	8006	Sagar Lonial, MD	First clinical (phase 1b/2a) study of iberdomide (CC-220; IBER), a CELMoD, in combination with dexamethasone (DEX) in patients (pts) with relapsed/refractory multiple myeloma (RRMM)
Hall D1	4:30PM - 6:00PM	Poster Discussion Session	9022	Taofeek Kunle Owonikoko, MD, PhD, MS	A phase II study of talazoparib (BMN 673) in patients with homologous recombination repair deficiency (HRRD) positive stage IV squamous cell lung cancer (Lung-MAP Sub-Study, S1400G).

Monday, June 3, 2019

Location	Time	Session Type	Abstract #	Presenter	Title
Hall A	8:00AM - 11:00AM	Poster Session (#215)	4110	Walid Labib Shaib, MD	Blood-based next-generation sequencing analysis of neuroendocrine tumors.
Hall A	8:00AM - 11:00AM	Poster Session (#364)	8038	Jonathan L. Kaufman, MD	Efficacy and safety of daratumumab, lenalidomide, and dexamethasone (D-Rd) in relapsed or refractory multiple myeloma (RRMM): Updated subgroup analysis of POLLUX based on cytogenetic risk.
Hall B1	8:24AM - 8:36AM	Oral Abstract Session	9002	Suresh S. Ramalingam, MD	E3A06: ECOG-ACRIN 5508: Pemetrexed, bevacizumab or the combination as maintenance therapy for advanced non-squamous NSCLC.
Hall D1	9:45AM - 9:57AM	Clinical Science Symposium	LBA108	R. Donald Harvey, PharmD, BCOP, FCCP	Impact of broadening clinical trial eligibility criteria for advanced non-small cell lung cancer patients: Real-world analysis.
S404	9:45AM - 10:45AM	Interactive Case-Based Session		Jonathan L. Kaufman, MD (Speaker)	The Role of Stem Cell Transplantation for Relapsed Multiple Myeloma
Hall A	1:15PM - 4:15PM	Poster Session (#45)	1551	Pamela Blair Allen, MD	Association of geographic clustering of cutaneous T-cell lymphoma in the state of Georgia with environmental exposure to benzene and trichloroethylene.
Hall A	1:15PM - 4:15PM	Poster Session (#169b)	TPS9603	Michael C. Lowe, MD, MA	Pilot integrated biomarker study of VX15/2503 in combination with ipilimumab and/or nivolumab in patients with resectable metastatic melanoma.
S504	1:35PM - 1:55PM	Education Session		J. William Eley, MD, MPH (Speaker)	Emotional Challenges Unique to Oncology Practice
Hall D1	5:00PM - 5:15PM	Education Session		Rathi Narayana Pillai, MD (Speaker)	Current Frontline Therapy Options for Squamous Cell Carcinoma

Tuesday, June 4, 2019

Location	Time	Session Type	Abstract #	Presenter	Title
S406	10:57AM - 11:09AM	Oral Abstract Session	9504	Ahmad A. Tarhini, MD, PhD	United States Intergroup E1609: A phase III randomized study of adjuvant ipilimumab (3 or 10 mg/kg) versus high-dose interferon-α2b for resected high-risk melanoma.

Networking Lounges

For more details including locations, hours, and special programming, please refer to the below links on the ASCO Annual Meeting website.

[Women's Networking Center](#)

Sign up to have a 25-minute, one-on-one mentoring conversation with a woman in the field of oncology. Mentors include Jane Meisel, MD and Katherine Virgo, PhD, FASCO.

[Trainee & Early-Career Oncologist Member Lounge](#)

The Trainee & Early Career Oncologist Member Lounge offers educational and scientific sessions, mentoring opportunities, and guided poster walks designed to support early career development.

[Publications Lounge](#)

Relax and connect with fellow authors, editorial board members, and reviewers and enjoy light refreshments each day. The Lounge will hold small events and plenary session live-streaming.

[Patient Advocate Lounge](#)

A designated space where advocates can gather in a relaxed environment to take a break and network with others.